Circulation, Vol 56, 114-118, Copyright © 1977 by American Heart Association
AC Carvalho, RS Lees, RA Vaillancourt and RW Colman
Intravascular coagulation (IVC) was evaluated in 19 patients with type II
and 11 with type IV hyperlipoproteinemia before and after clofibrate
therapy by measurements of soluble fibrin complexes (SFC) in plasma;
fibrinolysis was estimated by quantitation of fibrin (ogen) degradation
products in serum. Untreated type II and type IV patients had increased SFC
(P less than 0.01). The former also had activation of the intrinsic
coagulation pathway as evidenced by decreased plasma prekallikrein (P less
than 0.001), kallikrein inhibitors (P less than 0.001), and factor XII (P
less than 0.02). Although clofibrate treatment of the type II patients did
not change plasma lipids, it decreased intravascular coagulation,
apparently via decreased factor XII activation and stimulation of
fibrinolysis. In contrast, treated type IV patients had unchanged SFC and
FDP levels, despite decreased plasma triglycerides (P less than 0.01).
Clofibrate-induced changes in blood coagulation are independent of
lipid-lowering. Clofibrate therapy decreases intravascular coagulation in
type II patients and may help to prevent thromboembolic sequelae.
ARTICLES
Effect of clofibrate on intravascular coagulation in hyperlipoproteinemia
This article has been cited by other articles:
![]() |
K. M. McIntyre Cardiopulmonary Resuscitation and the Ultimate Coronary Care Unit JAMA, August 1, 1980; 244(5): 510 - 511. [Abstract] [PDF] |
||||
![]() |
K. M. McIntyre, A. F. Parisi, R. Benfari, A. H. Goldberg, and J. E. Dalen Pathophysiologic Syndromes of Cardiopulmonary Resuscitation Arch Intern Med, July 1, 1978; 138(7): 1130 - 1133. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1977 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |